Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Merck Resource Report Resource Website 10000+ mentions |
Merck (RRID:SCR_001287) | Merck | commercial organization | An American pharmaceutical company aiming to make a difference in the lives of people globally through their medicines, vaccines, biologic therapies and animal health products. | pharmaceutical, merck sharp & dohme corp, merck sharp and dohme corp, merck sharp and dohme, merck sharp & dohme corp., msd, medicine, endocrinology, neuroscience, oncology, respiratory, immunology, vaccine, animal health, veterinary |
uses: Kaggle uses: Tableau Desktop uses: FluoroFinder is affiliated with: European Federation of Pharmaceutical Industries and Associations is related to: eTRIKS is related to: OncoTrack is related to: European Lead Factory is related to: GetReal is related to: Investigator Databank is related to: Kinetics for Drug Discovery is related to: MIP-DILI is related to: ORBITO is related to: PharmaCog is related to: Asian Cancer Research Group is related to: Open PHACTS is related to: Collaboratory of AIDS Researchers for Eradciation (CARE) is parent organization of: MEDINA Foundation is parent organization of: Asian Cancer Research Group is parent organization of: Asia Training Consortium |
Diabetes, Cancer, Cardiovascular disease, Infectious disease | Crossref funder ID: 100004334, grid.417993.1, Wikidata: Q247489, ISNI: 0000 0001 2260 0793, nlx_152409 | https://ror.org/02891sr49 | SCR_001287 | Merck and Co., Merck and Co. Inc., Merck & Co. Inc., Merck & Co. | 2026-07-25 12:05:02 | 10277 | ||||||
|
Asian Cancer Research Group Resource Report Resource Website 1+ mentions |
Asian Cancer Research Group (RRID:SCR_004001) | ACRG | consortium, data or information resource, portal, data set, organization portal | An independent, not-for-profit consortium to accelerate research, and improve treatment for patients affected with the most commonly-diagnosed cancers in Asia by generating a genomic data resource for the most prevalent cancers in Asia. ACRG is focusing its initial efforts on Asian liver, gastric and lung cancers. Goals * Generate comprehensive genomics data sets for Asia-prevalent cancers * Conduct all research under good clinical practices and in accordance with local laws * Uncover key mutations and pathways for developing targeted therapies * Discover molecular tumor classifiers for patient stratification * Discover prognostic markers to identify high-risk patients * Freely share resulting raw data with scientific community to empower researchers globally and enable development of new diagnostics and medicines * Publish data analysis results jointly in prominent scientific journals Over the next two years, Lilly, Merck and Pfizer have committed to create an extensive pharmacogenomic cancer database that will be composed of data from approximately 2,000 tissue samples from patients with lung and gastric cancer that will be made publicly available to researchers and, over time, further populated with clinical data from a longitudinal analysis of patients. Comparison of the contrasting genomic signatures of these cancers could inform new approaches to treatment. Lilly has assumed responsibility for ultimately providing the data to the research public through an open-source concept managed by Lilly''''s Singapore research site. Moreover, Lilly, Merck and Pfizer will each provide technical and intellectual expertise. One dataset can be found at http://gigadb.org/dataset/100034 | asia, genomics, drug discovery, liver, gastric, lung, database, whole genome-wide study, drug development, basic research, data sharing, drug, oncology, pharmacogenomic, tissue, clinical, longitudinal |
uses: Gene Expression Omnibus uses: GigaDB is listed by: Consortia-pedia is related to: Merck is related to: Pfizer Animal Genetics is related to: BGI; Shenzhen; China has parent organization: Merck |
Eli Lilly and Company ; Merck ; Pfizer |
nlx_158412 | SCR_004001 | 2026-07-31 09:25:41 | 1 | ||||||||
|
MEDINA Foundation Resource Report Resource Website 1+ mentions |
MEDINA Foundation (RRID:SCR_004079) | MEDINA | portal, organization portal, data or information resource, service resource | A non-profit research center established through a public-private alliance between the Regional government of Andalusia, the pharmaceutical company Merck Sharp & Dohme Spain S.A. (MSD), and the University of Granada, that is focused on: # Discovery of new compounds and therapies as new leads for drug development # Contract Research Services: High throughput screening services for lead discovery, ADME/TOX, bioanalysis and metabolomics MEDINA offers 1) natural products screening services for lead discovery on therapeutic targets developed by the customers and 2) compound profiling services for their drug candidates, using a counterscreening panel designed to determine potential risks in cardiovascular safety and drug-drug interactions. | high throughput screening, bioanalysis, metabolomics, medicine, drug candidate, drug, drug discovery, natural product, oncology, neurodegeneration |
is related to: European Gram Negative AntiBacterial Engine has parent organization: Merck has parent organization: University of Granada; Granada; Spain |
Infectious disease, Parasitic disease, Cancer | nlx_158529 | SCR_004079 | Fundaci��n MEDINA (Centro de Excelencia en Investigaci��n de Medicamentos Innovadores en Andalucia), Fundacion MEDINA, Fundaci��n Centro de Excelencia en Investigaci��n de Medicamentos Innovadores en Andaluc��a Medina, Fundaci��n MEDINA | 2026-07-31 09:25:42 | 6 | |||||||
|
Asia Training Consortium Resource Report Resource Website |
Asia Training Consortium (RRID:SCR_004014) | ATC | consortium, data or information resource, portal, training resource, organization portal, short course | Consortium of pharmaceutical companies and clinical research organizations, plus one regional association, that are pooling their resources to deliver quality training courses for clinical research professionals in the Asia Pacific region. The collaborative training initiatives aim to resolve issues of redundant and duplicate trainings, less than optimal class sizes and lower than ideal training frequencies, all of which are prevalent in the region. ATC also hopes to significantly enhance the number and quality of professionals to meet the resource demands of the globalized industry. The first target audience would be clinical trial investigators and clinical trial management staff - with priorities provided to clinical trial associates, clinical trial project managers, and clinical research managers. As of 2014, 900 days of ATC courses have been taught in classrooms throughout Asia. The ATC''s Foundations of Clinical Project Management is a regularly offered in Shanghai and is available on-line in English and Mandarin. | drug development, tool development, drug, healthcare, pharmaceutical, clinical, clinical research organization, clinical project management, project management, clinical trial |
is listed by: Consortia-pedia has parent organization: Merck |
Annual dues | nlx_158433 | SCR_004014 | 2026-07-31 09:25:42 | 0 | ||||||||
|
European Lead Factory Resource Report Resource Website 1+ mentions |
European Lead Factory (RRID:SCR_003858) | ELF | nonprofit organization | Consortium that promotes the discovery of novel small molecule candidates suitable for subsequent optimization either to drug candidates or to high-quality pharmacological tools for the experimental validation of targets using open innovation and crowd sourcing. It is designed to provide best-in-class resources and funding-in-kind, to academics or small and medium enterprises (SMEs) who are working on promising biology targets or chemistry scaffolds. Screening of compounds to assess their activity is also funded and performed by the EU Lead Factory, with collaboration to help develop an Improved Hit List from the Qualified Hit List. They will provide collaborative screening of previously safeguarded, high quality corporate compounds. Around 300,000 compounds in the EFPIA Compound Collection, contributed by EFPIA members, will be screened against both commercially contributed biology targets and targets from public sources. The second phase of the consortium is to build a substantial new Public Compound Collection of around 200,000 compounds. Together, the EFPIA and Public compound collections will form a 500,000-strong Joint European Compound Collection. Target program owners and compound contributors will receive a Qualified Hit List (QHL) of up to 50 compounds complete with relevant information to help in the development of an Improved Hit List (IHL). Target program owners, will have exclusive access to threshold active compounds in their QHL. After the three-year exclusivity period, QHL/IHL information will be made public. Milestone payments are due if direct exploitation proceeds, not for research use. And owners and contributors will give EFPIA participants the right to submit a first bid (which they do not have to accept). | drug, crowd sourcing, drug candidate, pharmacological tool, target, oncology, drug discovery, drug development, lead structure, lead, compound, lead molecule, tool development, biomarker, small molecule, basic science, screening |
is listed by: Consortia-pedia is related to: Janssen Research and Development is related to: Merck is related to: BioAscent is related to: ChemAxon is related to: Edelris is related to: GABO:mi is related to: Lead Discovery Center is related to: Mercachem is related to: Pivot Park Screening Centre is related to: Sygnature Discovery is related to: Syncom is related to: Taros is related to: University of Dundee College of Life Sciences; Scotland; United Kingdom is related to: Leiden University; Leiden; Netherlands is related to: Max Planck Institute of Molecular Physiology; Dortmund; Germany is related to: Radboud University; Nijmegen; The Netherlands is related to: University of Groningen; Groningen; Netherlands is related to: Technical University of Denmark; Lyngby; Denmark is related to: TI Pharma is related to: University of Duisburg-Essen; North Rhine-Westphalia; Germany is related to: University of Leeds; West Yorkshire; United Kingdom is related to: University of Nottingham; Nottingham; United Kingdom is related to: VU University; Amsterdam; Netherlands has parent organization: TI Pharma has parent organization: Taros |
Innovative Medicines Initiative 115489; EFPIA |
nlx_158182, grid.498269.8 | https://ror.org/02gxafv90 | SCR_003858 | EU Lead Factory | 2026-07-25 12:05:44 | 6 | ||||||
|
FluoroFinder Resource Report Resource Website 1+ mentions |
FluoroFinder (RRID:SCR_015485) | service resource | Platform provides tools and web services for multicolor fluorescence experiment design, flow cytometry, and microscopy. Provides online spectra viewer and flow cytometry panel design tools and spectral analysis. By integrating experiment design tools featuring preloaded instrument configurations with comprehensive antibody database, panel builder speeds up flow cytometry experiment design. | Multicolor fluorescence experiment design tools and web services, flow cytometry, microscopy, fluorescence, FluoroFinder, panel builder, flow cytometry experiment design |
is used by: University of Michigan Medical School; Michigan; USA is used by: Merck is used by: ARIAD is used by: University of Washington School of Medicine; Washington; USA is used by: Celgene is used by: University of Florida College of Medicine; Florida; USA is recommended by: University of Rochester Medical Center Neurobiology and Anatomy |
SCR_015485 | 2026-07-25 12:08:06 | 7 | |||||||||||
|
Tableau Desktop Resource Report Resource Website 10+ mentions |
Tableau Desktop (RRID:SCR_013994) | data visualization software, software application, data processing software, software resource, data analytics software | A software application which utilizes drag-and-drop to create data visualizations of various formats. Users can collaborate on and discuss data and graphs that can be created from spreadsheets, databases, and big data sources. Three versions of Tableau Desktop are available: Tableau Server, Tableau Online, and Tableau Reader. | data analytics, data visualization, drag and drop |
is used by: Merck is listed by: Connected Researchers is related to: Connected Researchers |
Free ; Price (for certain editions and packages) |
Free, Fee (for certain editions and packages) | http://www.tableau.com | SCR_013994 | 2026-07-31 09:27:21 | 20 | ||||||||
|
ORBITO Resource Report Resource Website 1+ mentions |
ORBITO (RRID:SCR_003876) | ORBITO | portal, consortium, data or information resource, organization portal | Project that aims to increase understanding of how orally-administered drugs are taken up from the gastrointestinal tract into the body, and apply this knowledge to create new laboratory tests and computer models that will better predict the performance of these drugs in patients over a range of clinically relevant conditions. The integration of in vitro and in silico approaches will provide a biopharmaceutics toolkit, validated using clinical data, to accelerate drug development. Ultimately, the project will help to facilitate and speed up the formulation development process and significantly reduce the need for animal experiments in this area as well as for human clinical studies in the future. For patients, the main benefit will be in the form of high quality medicines where the dose required is well calculated and is released in a way that consistently provides an optimal clinical effect. | drug, drug development, tool development, computer model, drug absorption, oral drug, gastrointestinal tract, clinical, in vivo, in vitro, in silico, biopharmaceutics, dose, drug performance |
is listed by: Consortia-pedia is related to: AbbVie is related to: Janssen Research and Development is related to: Merck is related to: Orion is related to: Pfizer Animal Genetics is related to: Uppsala University; Uppsala; Sweden is related to: University of Copenhagen; Copenhagen; Denmark is related to: University of Greifswald; Mecklenburg-Vorpommern; Germany is related to: Goethe University Frankfurt am Main; Hessen; Germany is related to: Johannes Gutenberg University Mainz; Rhineland-Palatinate; Germany is related to: Catholic University of Leuven; Flemish Brabant; Belgium is related to: Medical Products Agency; Uppsala; Sweden is related to: University of Athens; Athens; Greece is related to: TNO is related to: University of Manchester; Manchester; United Kingdom is related to: University of Strathclyde; Glasgow; United Kingdom is related to: Simcyp is related to: Sirius Analytical is related to: Simulations Plus has parent organization: Uppsala University; Uppsala; Sweden |
Innovative Medicines Initiative ; EFPIA |
nlx_158204 | SCR_003876 | orbito - Innovative Tools for Oral Biopharmaceutics, Oral biopharmaceutics tools (ORBITO) | 2026-07-31 09:25:39 | 7 | |||||||
|
European Federation of Pharmaceutical Industries and Associations Resource Report Resource Website 10+ mentions |
European Federation of Pharmaceutical Industries and Associations (RRID:SCR_003820) | EFPIA | institution | Federation representing the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, it is the voice on the EU scene of 1,900 companies committed to researching, developing and manufacturing new medical treatments. In addition, it is active in partnering in EU Research programmes, such as the IMI (Innovative Medicines Initiative), Europe's largest public-private partnerships. They also work on corporate social responsibility initiatives with others healthcare stakeholders, such as patient groups and healthcare professionals. EFPIA has specialized committees and task forces focused on key areas of activity. EFPIA also includes two specialized groups focusing on vaccines and biotechnology, respectively: * Vaccines Europe (formerly European Vaccine Manufacturers, EVM) produces approximately 80% of vaccines used worldwide * European Biopharmaceutical Enterprises (EBE) harness biotechnology to develop approximately one-fifth of new medicines | pharmaceutical, medicine, vaccine, biotechnology, manufacturing, corporate |
is affiliated with: Merck is affiliated with: Roche is related to: Innovative Medicines Initiative is parent organization of: Innovative Medicines Initiative |
nlx_158124, grid.484123.8, ISNI: 0000 0000 9246 8110, Wikidata: Q1376562 | https://ror.org/00g1x4v36 | SCR_003820 | 2026-07-25 12:05:43 | 12 | ||||||||
|
Kaggle Resource Report Resource Website 100+ mentions Issue |
Kaggle (RRID:SCR_013852) | people resource | A group resource which connects organizations to data scientists who produce accurate predictive models. Kaggle uses competition to incentivize data scientists to create the most accurate and precise predictive models for an organization’s sets of data. The data scientist or team of data scientists who creates the best model is awarded a prize and the organization receives the predictive model. | group, data scientist, predictive model, competition, recruitment |
is used by: Merck is used by: Mayo Clinic is listed by: Connected Researchers is related to: Connected Researchers |
SCR_013852 | 2026-07-25 12:07:56 | 210 | |||||||||||
|
MIP-DILI Resource Report Resource Website 1+ mentions |
MIP-DILI (RRID:SCR_003870) | MIP-DILI | portal, consortium, data or information resource, organization portal | Consortium that brings together Europe's top industrial and academic experts to develop new tests that will help researchers detect potential liver toxicity issues much earlier in drug development, saving many patients from the trauma of liver failure. The team aims to deepen the understanding of the science behind drug-induced liver injury, and use that knowledge to overcome the many drawbacks of the tests currently used. A major focus will be on a systematic and evidence-based evaluation of both currently available and new laboratory test systems, including cultures of liver cells in one-dimensional and three dimensional configurations. The project will also develop models that take into account the natural differences between patients. This is important because factors such as certain genes, the liver's immune response, and viral infections have all been associated with an increased risk of DILI. The project will seek to address the current lack of human liver cells available to researchers by using induced pluripotent stem cells (iPSCs) generated from patients who are particularly sensitive to DILI. Another strand of the project will develop computer models to unravel the complex, often inter-related mechanisms behind DILI. Finally, the team will assess how accurate the results of laboratory tests are at predicting actual outcomes in patients. | drug, liver, toxicity test, toxicity, drug development, tool development, liver toxicity, preclinical, model, induced pluripotent stem cell, liver cell, gene, immune response, computer model, outcome |
is listed by: Consortia-pedia is related to: Abbott Diagnostics is related to: Janssen Research and Development is related to: Merck is related to: Orion is related to: University of Liverpool; Liverpool; United Kingdom is related to: University of Freiburg; Baden-Wurttemberg; Germany is related to: German Cancer Research Center is related to: Karolinska Institute; Stockholm; Sweden is related to: University of Rennes 1; Rennes; France is related to: Leiden University; Leiden; Netherlands is related to: Utrecht University; Utrecht; Netherlands is related to: VU University; Amsterdam; Netherlands is related to: Cellartis is related to: CXR Biosciences is related to: Interface Europe is related to: KaLy-Cell is related to: Lhasa Limited is related to: SOLVO Biotechnology has parent organization: Interface Europe |
Innovative Medicines Initiative 115336; EFPIA |
nlx_158195 | SCR_003870 | Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI), Mechanism based Integrated systems for the Prediction of Drug Induced Liver Injury, Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury | 2026-07-31 09:25:40 | 2 | |||||||
|
Kinetics for Drug Discovery Resource Report Resource Website 1+ mentions |
Kinetics for Drug Discovery (RRID:SCR_003868) | K4DD | portal, consortium, data or information resource, organization portal | Project whose goal is to improve understanding of how potential drugs bind with their target, and develop methods and tools to allow researchers to study drug-target interactions with greater ease. These tools would help researchers to determine whether a drug candidate is likely to be safe and effective much earlier in the drug development process. The first goal of the team is to enhance understanding of binding kinetics; exactly how do small molecules interact with their targets? Ultimately, the project aims to develop a range of robust techniques, methods and models that could be easily incorporated into the drug development pathway and enable scientists and drug designers worldwide to reliably predict a molecule's kinetic properties (its "kinotype"). This information will allow drug developers to more easily determine the safety and efficacy of a molecule and will weed out ineffective or unsafe molecules earlier in the drug development process. Eventually, the project also hopes to raise awareness of the importance of considering the kinetic aspects of drug-target interactions throughout drug development. | drug-target interaction, drug, drug development, tool development, binding kinetics, small molecule, target, kinotype, kinetics, bind |
is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Leiden University; Leiden; Netherlands is related to: TI Pharma is related to: Imperial College London; London; United Kingdom is related to: Ruhr University Bochum; North Rhine-Westphalia; Germany is related to: University of Vienna; Vienna; Austria is related to: University of Dundee; Scotland; United Kingdom is related to: University of Nottingham; Nottingham; United Kingdom is related to: University of Oxford; Oxford; United Kingdom is related to: European ScreeningPort is related to: Heptares Therapeutics is related to: Heidelberg Institute for Theoretical Studies; Heidelberg; Germany is related to: Sierra Sensors has parent organization: Leiden University; Leiden; Netherlands has parent organization: TI Pharma |
Innovative Medicines Initiative 115366; EFPIA |
nlx_158193 | SCR_003868 | 2026-07-31 09:25:39 | 3 | ||||||||
|
Investigator Databank Resource Report Resource Website |
Investigator Databank (RRID:SCR_003866) | CPID | consortium, data or information resource, portal, community building portal, organization portal | Consortium between several pharmaceutical companies to develop a database that shares clinical trial investigator information that each company has on file to reduce administrative burden for investigators and to increase visibility of qualified investigators to research sponsors. Hosted by a 3rd party, DrugDev, it is the one place where pharmaceutical companies can share investigator and site information and investigators can view, edit, and comment on their own information. Industry members will be able share information from their clinical trial management systems including investigator / site contact details, GCP training records, past trial participation, and recruitment history. Upon investigator opt-in, this information is used by each participating company to identify sites for upcoming studies; to help set recruitment targets and timelines; and to share start-up documents such as CV, GCP, and site profile forms. The Databank has grown to include nearly 180,000 investigators (May 2014) and is already bringing benefits to its member companies in identifying qualified investigators for their studies. It also reported the inclusion of 7,335 protocols and 50K sites, representing a patient population around 1.9M. | drug development, clinical trial, pharmaceutical, investigator, sponsor, data sharing, protocol, drug, tool development, database, people resource |
uses: DrugDev is listed by: Consortia-pedia is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: DrugDev has parent organization: Janssen Research and Development has parent organization: DrugDev |
The community can contribute to this resource | nlx_158192 | SCR_003866 | Cross-Pharmaceutical Investigator Databank | 2026-07-31 09:25:40 | 0 | |||||||
|
PharmaCog Resource Report Resource Website 10+ mentions |
PharmaCog (RRID:SCR_003878) | PharmaCog | portal, consortium, data or information resource, organization portal | Project aiming to tackle bottlenecks in Alzheimer''''s disease research and drug discovery by developing and validating new tools to test candidate drugs for the treatment of symptoms and disease in a faster and more sensitive way. They will provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines. By bringing together databases of previously conducted clinical trials and combining the results from blood tests, brain scans and behavioral tests, the scientists will develop a ''''signature'''' that gives more accurate information on the progression of the disease and the effect of candidate drugs than current methods do. The scientists will conduct parallel studies in laboratory models, healthy volunteers and patients in order to better predict good new drugs as early as possible. This will enable them, for instance, to find out how memory loss in Alzheimer''''s disease can be simulated in healthy volunteers, for example with sleep deprivation or drugs that temporarily affect the memory, in order to test the effect of candidate-medicines early in the drug development process. | drug, biomarker, drug discovery, model, tool development, drug development, medicine, clinical, pre-clinical, pharmacology, disease progression, cognitive impairment |
is listed by: Consortia-pedia is related to: Merck is related to: Janssen Research and Development is related to: Roche is related to: Eisai is related to: Aix-Marseille University; Provence-Alpes-Cote d'Azur; France is related to: Alzheimer Europe is related to: French National Center for Scientific Research is related to: Greek Association of Alzheimers Disease and Related Disorders is related to: August Pi i Sunyer Biomedical Research Institute; Barcelona; Spain is related to: National Institute of Health and Medical Research; Rennes; France is related to: Mario Negri Institute for Pharmacological Research; Milan; Italy is related to: University of Murcia; Murcia; Spain is related to: Catholic University of the Sacred Heart; Milan; Italy is related to: University of Foggia; Foggia; Italy is related to: University of Genoa; Genoa; Italy is related to: University of Perugia; Perugia; Italy is related to: University of Verona; Verona; Italy is related to: University of Leipzig; Saxony; Germany is related to: Lille 2 University of Health and Law; Lille; France is related to: University of Exeter; Exeter; United Kingdom is related to: Innovative Concepts in Drug Development is related to: AlzProtect is related to: Qualissima is related to: Exonhit Therapeutics is related to: University of Bristol; Bristol; United Kingdom is related to: European Medicines Agency has parent organization: Lille 2 University of Health and Law; Lille; France has parent organization: Alzheimer Europe has parent organization: Aix-Marseille University; Provence-Alpes-Cote d'Azur; France |
Innovative Medicines Initiative 115009; EFPIA |
nlx_158206 | SCR_003878 | Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development, Pharma-Cog | 2026-07-31 09:25:40 | 13 | |||||||
|
Open PHACTS Resource Report Resource Website 10+ mentions |
Open PHACTS (RRID:SCR_005050) | OPS | consortium, data or information resource, portal, database, software resource, organization portal | Project that developed an open access discovery platform, called Open Pharmacological Space (OPS), via a semantic web approach, integrating pharmacological data from a variety of information resources and tools and services to question this integrated data to support pharmacological research. The project is based upon the assimilation of data already stored as triples, in the form subject-predicate-object. The software and data are available for download and local installation, under an open source and open access model. Tools and services are provided to query and visualize this data, and a sustainability plan will be in place, continuing the operation of the Open PHACTS Discovery Platform after the project funding ends. Throughout the project, a series of recommendations will be developed in conjunction with the community, building on open standards, to ensure wide applicability of the approaches used for integration of data. | drug, enzyme family, structure, receptor, target, ki, pathway, pharmacology, enzyme, small molecule, data mining, annotation, drug discovery, drug development, pharmacological profile, pharmacokinetic, admet data, biological target, chemical, linked data, rdf, nanopublication, platform, semantic technology, text mining, bioinformatics, cheminformatics, interoperability, chemistry, data provenance, compound, small molecule, semantic integration, drug discovery |
uses: CHEBI uses: ChemSpider uses: ConceptWiki uses: DrugBank uses: ENZYME uses: UniProt uses: Gene Ontology uses: WikiPathways is listed by: Consortia-pedia is listed by: FORCE11 is related to: Nanopub.org is related to: eTRIKS is related to: Janssen Research and Development is related to: Almirall is related to: ESTEVE is related to: Merck is related to: Pfizer Animal Genetics is related to: VU University; Amsterdam; Netherlands is related to: European Bioinformatics Institute is related to: Maastricht University; Maastricht; Netherlands is related to: University of Bonn; Bonn; Germany is related to: Royal Society of Chemistry is related to: Spanish National Cancer Research Center is related to: Netherlands Bioinformatics Centre is related to: SIB Swiss Institute of Bioinformatics is related to: Technical University of Denmark; Lyngby; Denmark is related to: University of Santiago de Compostela; Santiago de Compostela; Spain is related to: University of Vienna; Vienna; Austria is related to: University of Hamburg; Hamburg; Germany is related to: University of Manchester; Manchester; United Kingdom is related to: BioSolveIT is related to: ConnectedDiscovery is related to: OpenLink Software is related to: SciBite is related to: Open PHACTS Foundation has parent organization: University of Vienna; Vienna; Austria |
Innovative Medicines Initiative grant 115191; EFPIA ; Open PHACTS Foundation |
PMID:22683805 | Open unspecified license, Registration required, Non-commercial | r3d100011550, nlx_144033 | https://www.force11.org/node/4684, http://www.imi.europa.eu/content/open-phacts, https://doi.org/10.17616/R3T63F | SCR_005050 | Open PHACTS - Open Pharmacological Space, OpenPhacts.org, Open Pharmacological Space, Open Pharmacological Concepts Triple Store, OpenPHACTS, Open PHACTS: Open Pharmacological Space | 2026-07-31 09:26:03 | 11 | ||||
|
GetReal Resource Report Resource Website 10+ mentions |
GetReal (RRID:SCR_003862) | GetReal | portal, consortium, data or information resource, organization portal | Consortium that aims to improve the efficiency of the medicine development process by better incorporating estimates of relative effectiveness into drug development and to enrich decision-making by regulatory authorities and health technology assessment (HTA) bodies through: * Bringing together regulators, HTA bodies, academics, companies, patients and other societal stakeholders; * Assessing existing processes, methodologies, and key research issues; * Proposing innovative (and more pragmatic) trial designs and assessing the value of information; * Proposing and testing innovative analytical and predictive modelling approaches; * Assessing operational, ethical, regulatory issues and proposing and testing solutions; * Creating new decision making frameworks, and building open tools to allow for the evaluation of development programs and use in the assessment of the value of new medicines; * Sharing and discussing deliverables with, among others, Pharmaceutical companies, regulatory authorities, HTA / reimbursement agencies, clinicians and patient organizations; * Developing training activities for researchers, decision makers and societal stakeholders in the public and private sector in order to increase knowledge about various aspects of relative effectiveness. The expected impact is that it will contribute to the knowledge base, particularly to inform clinical decision making and improve the efficiency of the R&D process. GETREAL will help to generate a consensus on best practice in the timing, performance and use of real life clinical studies in regulatory and reimbursement decision-making. It will also help to create a strong platform for the communication of results and for future discussions in this important area. | drug, health technology assessment, clinical, drug development, basic research, data sharing |
is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: European Medicines Agency is related to: EORTC is related to: French National Authority for Health is related to: London School of Hygiene and Tropical Medicine; London; United Kingdom is related to: University of Ioannina; Ioannina; Greece is related to: University of Bern; Bern; Switzerland is related to: University of Leicester; Leicester; United Kingdom is related to: International Alliance of Patients Organizations |
Innovative Medicines Initiative ; EFPIA |
nlx_158185 | SCR_003862 | 2026-07-31 09:25:40 | 40 | ||||||||
|
Collaboratory of AIDS Researchers for Eradciation (CARE) Resource Report Resource Website |
Collaboratory of AIDS Researchers for Eradciation (CARE) (RRID:SCR_013681) | CARE | portal, consortium, data or information resource, organization portal | The Collaboratory of AIDS Researchers for Eradication (CARE) is a consortium of scientific experts in the field of HIV latency from several U.S. and European academic research institutions as well as Merck Research Laboratories working together to find a cure for HIV. | AIDS, HIV, drug development, data-sharing enabler, |
is related to: University of North Carolina at Chapel Hill School of Medicine; North Carolina; USA is related to: Gladstone Institute of Neurological Disease is related to: UCSF School of Medicine; California; USA is related to: Case Western Reserve University; Ohio; USA is related to: Merck is related to: UC Davis School of Medicine; California; USA is related to: University of California at San Diego; California; USA is related to: University of Utah School of Medicine; Utah; USA is related to: University of Minnesota Twin Cities; Minnesota; USA |
NIAID ; NIMH |
SCR_013681 | 2026-07-31 09:27:19 | 0 | |||||||||
|
OncoTrack Resource Report Resource Website 1+ mentions |
OncoTrack (RRID:SCR_003767) | OncoTrack | portal, consortium, data or information resource, organization portal | An international consortium to develop and assess novel approaches to identify and characterize biological markers for colon cancer that will deepen the understanding of the variable make-up of tumors and how this affects the way patients respond to treatment. They will use cutting edge laboratory-based genome sequencing techniques coupled to novel computer modelling approaches to study both the biological heterogeneity of colon cancers (i.e. patient to patient variability) as well as tumor variation within the patient for example, by comparing primary tumors with metastases. This five year project brings together top scientists from European academic institutions offering a wide range of expertise, and partners them with pharmaceutical companies. The project is based on the premise that this genetic and epigenetic information, combined with a description of the molecular pathology of the tumor, will allow OncoTrack to generate a more accurate in-silico model of the cancer cell. This will facilitate the identification of predictive markers that can be used to guide the optimal therapy strategy at the level of the individual patient - and will also provide on-going prognostic guidance for the clinician. This project will not only advance understanding of the fundamental biology of colon cancers but will provide the means and approach for the identification of previously undetected biomarkers not only in the cancer under study, but potentially also in other solid cancers and, in doing so, open the door for personalized management of the oncology patient. | oncology, biomarker, diagnosis, basic science, genome sequencing, computer modelling, genetic, epigenetic, pathology, model, cancer cell, colon, cancer, treatment, genomics, clinical, systems biology, in-silico model, patient variability, tumor variability |
uses: GenomeWeb uses: eTRIKS is listed by: Consortia-pedia is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: Charite - Universitatsmedizin Berlin; Berlin; Germany is related to: Max Planck Institute for Molecular Genetics; Berlin; Germany is related to: Medical University of Graz; Graz; Austria is related to: Paris-Sud University; Paris; France is related to: Dresden University of Technology; Saxony; Germany is related to: University College London; London; United Kingdom is related to: Uppsala University; Uppsala; Sweden is related to: Stockholm University; Stockholm; Sweden is related to: Vall d'Hebron Institute of Oncology; Barcelona; Spain is related to: Alacris Theranostics is related to: Experimental Pharmacology and Oncology Berlin-Buch is related to: GABO:mi is related to: International Prevention Research Institute has parent organization: Max Planck Institute for Molecular Genetics; Berlin; Germany |
Innovative Medicines Initiative ; EFPIA |
nlx_158037 | SCR_003767 | OncoTrack - Methods for systematic next generation oncology biomarker development, Onco Track | 2026-07-31 09:25:38 | 9 | |||||||
|
eTRIKS Resource Report Resource Website 10+ mentions |
eTRIKS (RRID:SCR_003765) | eTRIKS | consortium, data or information resource, portal, service resource, organization portal | Research informatics and analytics platform for the IMI OncoTrack consortium. | data sharing, drug discovery, translational research, informatics, knowledge management, metadata standard, platform, analytics, tool development, bio.tools |
uses: tranSMART is used by: U-BIOPRED is used by: Predict-TB is used by: OncoTrack is used by: ABIRISK is used by: RA MAP is listed by: Consortia-pedia is listed by: Debian is listed by: bio.tools is related to: Roche is related to: Janssen Research and Development is related to: Merck is related to: Pfizer Animal Genetics is related to: Imperial College London; London; United Kingdom is related to: French National Center for Scientific Research is related to: Clinical Data Interchange Standards Consortium is related to: University of Luxembourg; Luxembourg; Luxembourg is related to: IDBS is related to: BioSci Consulting is related to: TraIT is related to: EMIF is related to: Open PHACTS has parent organization: Imperial College London; London; United Kingdom |
Innovative Medicines Initiative ; EFPIA |
PMID:29482119 | biotools:eTRIKS, nlx_158034 | https://bio.tools/eTRIKS | SCR_003765 | European Translational Information and Knowledge Management Services, European Translational Information & Knowledge Management Services | 2026-07-31 09:25:37 | 10 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the Neuroscience Information Framework Project, designed to serve the biomedical research community. NIF maintains the largest searchable collection of neuroscience data, the largest catalog of biomedical resources, and the largest ontology for neuroscience on the web. We welcome all feedback and suggestions and are actively looking for resource providers to make their resources accessible through NIF. Learn about the tools available to help you share your data and discover a dynamic inventory of Web-based neuroscience resources.
